These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 21927844

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period.
    Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M.
    J Infect Chemother; 2012 Aug; 18(4):436-43. PubMed ID: 22205543
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study.
    Kadota JI, Kurashima A, Suzuki K.
    J Infect Chemother; 2017 May; 23(5):293-300. PubMed ID: 28254517
    [Abstract] [Full Text] [Related]

  • 8. [Effect of combined chemotherapy following the guidelines on treatment for Mycobacterium avium complex pulmonary disease].
    Kobashi Y, Okimoto N, Matsushima T, Shigetou E, Kuraoka T, Takeyama H, Eda R, Yano S, Kobayashi K, Ohnishi T, Mori K, Ueda Y, Moritaka T, Nishimura K, Abe T.
    Kekkaku; 2002 Jun; 77(6):435-41. PubMed ID: 12136597
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease.
    Fukushima K, Kitada S, Komukai S, Kuge T, Matsuki T, Kagawa H, Tsujino K, Miki M, Miki K, Kida H.
    Sci Rep; 2021 Jan 13; 11(1):1178. PubMed ID: 33441977
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of fluoroquinolone-containing regimens in treating pulmonary Mycobacterium avium complex disease: A propensity score analysis.
    Shuto H, Komiya K, Goto A, Kan T, Honjo K, Uchida S, Takikawa S, Yoshimatsu T, Yamasue M, Hiramatsu K, Kadota JI.
    PLoS One; 2020 Jan 13; 15(7):e0235797. PubMed ID: 32645105
    [Abstract] [Full Text] [Related]

  • 16. Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy.
    Ito Y, Miwa S, Shirai M, Kanai M, Fujita K, Ohba H, Iwaizumi E, Oshima T, Kojima S, Suda T, Hayakawa H.
    Respir Med; 2020 Aug 13; 169():106025. PubMed ID: 32442113
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease.
    Moon SM, Kim SY, Kim DH, Huh HJ, Lee NY, Jhun BW.
    Antimicrob Agents Chemother; 2022 Apr 19; 66(4):e0202721. PubMed ID: 35266825
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.